- $22.41bn
- $21.91bn
- $606.42m
Insmed hits more than two-decade high as rare lung disease drug succeeds in trial
U.S. STOCKS ON THE MOVE-Citigroup, Boeing, Calavo Growers
U.S. STOCKS ON THE MOVE-Academy Sports, energy stocks, FirstEnergy
Insmed soars as rare lung disease drug succeeds in mid-stage trial; drags rivals down
U.S. STOCKS ON THE MOVE-United Natural Foods, Insmed, MacroGenics
Insmed soars as blood pressure drug succeeds in mid-stage trial
Insmed's blood pressure drug meets main goal in mid-stage trial (updated)
Brief: Insmed Announces Positive Topline Results From Phase 2B Study Of Its Blood Pressure Drug
Insmed's blood pressure drug meets main goal in mid-stage trial
Insmed Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Insmed Q1 Revenue USD 92.8 Million Vs. IBES Estimate USD 92.1 Million
Insmed Inc reports results for the quarter ended December 31 - Earnings Summary
U.S. STOCKS ON THE MOVE-Repligen, Mangoceuticals, Insmed
U.S. STOCKS ON THE MOVE-Sabre, MicroStrategy, Repligen
Insmed falls on weak 2025 sales forecast for lead drug
Brief: Insmed Q4 Revenue USD 104.4 Million Vs. IBES Estimate USD 102.8 Million
Brief: Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
U.S. RESEARCH ROUNDUP-Altus Power, Amazon, Nevro
Brief: Insmed Provides Business Update At 43Rd Annual J.P. Morgan Healthcare Conference